Lupin launches Merzee capsules in the United States
Drug Approval

Lupin launches Merzee capsules in the United States

Merzee is a generic equivalent of Taytulla of Allergan Pharmaceuticals International

  • By IPP Bureau | April 07, 2022

Lupin announced that it has launched Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg, in the US market, under exclusive license, marketing and distribution agreement with Slayback Pharma. Slayback had earlier launched this product in the US in February 2021.

 Merzee  (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg is a generic equivalent of Taytulla (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg of Allergan Pharmaceuticals International.

Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1 mg/20 mcg (RLD: Taytulla) had estimated annual sales of US $ 90 million in the U.S. (IQVIA MAT February 2022).

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International